Skip to main content
. 2021 Aug 16;12:680177. doi: 10.3389/fpsyt.2021.680177

Table 1.

Maternal characteristics (n = 148).

Control Depressed SRI-Depressed SRI-Non-Depressed Test statistic
(n = 57) (n = 42) (n = 31) (n = 18) (p-value)
Maternal age (years) 32.9 ± 3.5 34.5 ± 4.5 33.9 ± 5.9 35.1 ± 5.1 F(3, 144) = 1.6 (0.2)
Maternal weight at 36-weeks' (kg) 75.1 ± 9.7 81.9 ± 16.0 82.5 ± 15.0 79.6 ± 9.8 F(3, 144) = 3.2 (0.02)*
Parity 0 (0, 1) 0 (0, 1) 0 (0, 1) 0 (0, 0) H(3) = 1.9 (0.6)
Education (total years) 18.7 ± 3.1 18.0 ± 3.9 17.3 ± 3.6 18.3 ± 3.7 F(3, 144) = 1.1 (0.3)
Alcohol during pregnancy (n total drinks) 0 (0, 2) 0 (0, 2) 0 (0, 2.5) 1 (0, 4.75) H(3) = 2.6 (0.5)
Smoking during pregnancy (n smoker/n non-smoker) 0/57 1/41 1/30 1/17 (0.2)
HAM-D at 36-weeks' 4.7 ± 2.3 12.7 ± 4.0 13.4 ± 3.1 6.0 ± 2.1 F(3, 144) = 88 (<0.001)***
SRI antidepressants ( n , [dose range])
Citalopram (n = 14) 10 [10–60 mg] 4 [10–50 mg]
Escitalopram (n = 7) 3 [5–20 mg] 4 [10 mg]
Fluoxetine (n = 5) 2 [20–80 mg] 3 [20–60 mg]
Paroxetine (n = 4) 3 [20–40 mg] 1 [30 mg]
Sertraline (n = 6) 4 [50–200 mg] 2 [75–200 mg]
Venlafaxine (n = 12) 9 [75–262.5 mg] 3 [75–150 mg]
Moclobemide (n = 1) 1 [150 mg]
Standardized daily SRI dose 1.5 (1.0, 2.0) 1.0 (1.0, 1.5) t(47) = 0.9 (0.4)
Length of gestational SRI exposure (days) 264 ± 36 260 ± 48 t(47) = 0.31 (0.8)

Continuous variables reported as mean ± SD if normally distributed, or median (first, third quartile) if skewed. Categorical variable reported as total number (n). Test statistics, degrees of freedom, and associated p-values are reported for between-group differences using: one-way ANOVA (F), Kruskal-Wallis test (H), Fisher's Exact test, or two-sample t-test (t), where appropriate. P-value significance levels: *p < 0.05, **p < 0.01, ***p < 0.001.

SRI, serotonin reuptake inhibitor; HAM-D, total score from Hamilton Rating Scale for Depression; kg, kilograms; mg, milligrams.

Alcohol during pregnancy represents n total standard drinks consumed during the course of pregnancy (study sample range: 0–52 total drinks).

Reversible monoamine oxidase inhibitors included in cohort as “SRI-exposed.”